The European long-acting bronchodilator market was valued at around $1.3 billion in 2018 and is anticipated to grow at a substantial rate of 2.6% during the forecast period. Major countries that will contribute to the long-acting bronchodilator market within the region includes UK, Germany, France, Italy, and Spain. A significant number of companies, research, the patient base has been observed in the market due to which a significant growth can be observed in the market. According to the International Monetary Fund (IMF), Europe is home to around 740 million people and the GDP of the European Union is $19.7 trillion in 2017. As per Organization for Economic Co-operation and Development (OECD), the self-reported asthma rate and COPD rate by European Union countries were 6.1% and 4.0% respectively and it has been found out that the rate of prevalence of diseases is higher in women as compared to men. This is expected to drive the regional business growth of the long-acting bronchodilator market.
To Request a Sample of our Report on European Long-Acting Bronchodilator Market: https://www.omrglobal.com/request-sample/european-long-acting-bronchodilator-market
The European long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the economies of the region such as the UK, Germany, France, Italy, Spain, and others. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
(Get 15% Discount on Buying this Report)
A full Report of European Long-Acting Bronchodilator Market is Available @ https://www.omrglobal.com/industry-reports/european-long-acting-bronchodilator-market
Long-Acting Bronchodilator Market Segmentation
By Route of Administration
- Oral
- Nasal
- Parenteral
- Inhalation
By Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
By End-User
- Homecare
- Hospitals and Clinics
Regional Analysis
- UK
- Germany
- France
- Italy
- Spain
Rest of Europe
Company Profiles
- Adamis Pharmaceuticals Corp.
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline PLC
- Novartis AG
- ResMed Corp.
- Pulmatrix Inc.
- Savara, Inc.
- Sunovion Pharmaceuticals
- Teva Pharmaceuticals Industries Ltd.
- Vitalograph Ltd.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
